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Introduction
Breast cancer is the leading cancer diagnosis and second-lead-
ing cause of cancer death for women in the United States (1). 
Patient prognosis is determined largely by stratification based 
on age, lymph node involvement, tumor grade, and tumor 
cell-surface expression of estrogen receptor (ER), progesterone 
receptor (PR), and human epidermal growth factor receptor 2 
(HER2) (2–7). Early diagnosis and targeted therapies, both hor-
monal and immunologic, are critical for the effective treatment 
of ER-, PR-, and HER2-positive disease. Given the lack of tar-
geted therapies for patients whose tumors do not express ER, 
PR, and HER2, termed triple-negative breast cancers, the sur-
vival benefit from recent therapeutic advances has eluded this 
group of patients. This is especially important for clinicians and 
patients, as triple-negative tumors present with higher grade at 
diagnosis and an increased incidence for disease relapse, early 
metastasis, and death (8–11).
Transcriptome profiling has defined 5 intrinsic molecular 
subtypes of breast cancer: luminal A, luminal B, HER2 enriched, 
basal-like, and claudin-low (12, 13). The basal-like and claudin-low 
subtypes are distinguished by increased expression of genes asso-
ciated with tumor cell proliferation and adaptive and innate immu-
nity (14, 15). Claudin-low tumors are further separated from bas-
al-like tumors by their decreased expression of cell-cell adhesion 
claudin proteins, increased expression of genes associated with 
epidermal-to-mesenchymal transition, and stem cell–like charac-
teristics (16). Importantly, basal-like and claudin-low tumors make 
up the majority of triple-negative tumors and have a significantly 
poorer prognosis than luminal and HER2-enriched tumors (17).
In addition to tumor-intrinsic genetic features, tumor growth 
is dependent on tumor-extrinsic factors, which include the tumor 
stroma and the local immune response (14, 18). Tumor-infiltrating 
lymphocytes (TILs)can have divergent effects in the tumor micro-
environment (TME). Whereas the presence of multiple immune 
cell types may herald productive antitumor immunity (15), TILs 
may also contribute to tumor progression through immune sup-
pression or the production of soluble factors that regulate cell pro-
liferation, migration, and angiogenesis (19).
While the presence of TILs is associated with an improvement 
in the survival of patients with multiple different tumor subtypes, 
this has not been found for specific subtypes of breast cancer. The 
luminal A subtype, which exhibits no appreciable immune infiltra-
tion, carries the best prognosis, whereas the basal-like and clau-
din-low subtypes exhibit a marked immune infiltrate with worse 
clinical outcomes (20). In this study, we sought to understand the 
mechanism by which immune infiltration is associated with poor 
clinical outcomes for patients with claudin-low tumors.
Claudin-low breast cancer is an aggressive subtype that confers poor prognosis and is found largely within the clinical triple-
negative group of breast cancer patients. Here, we have shown that intrinsic and immune cell gene signatures distinguish 
the claudin-low subtype clinically as well as in mouse models of other breast cancer subtypes. Despite adaptive immune cell 
infiltration in claudin-low tumors, treatment with immune checkpoint inhibitory antibodies against cytotoxic T lymphocyte–
associated protein 4 (CTLA-4) and programmed death receptor 1 (PD-1) were ineffective in controlling tumor growth. 
CD4+FoxP3+ Tregs represented a large proportion of the tumor-infiltrating lymphocytes (TILs) in claudin-low tumors, and 
Tregs isolated from tumor-bearing mice were able to suppress effector T cell responses. Tregs in the tumor microenvironment 
highly expressed PD-1 and were recruited partly through tumor generation of the chemokine CXCL12. Antitumor efficacy 
required stringent Treg depletion combined with checkpoint inhibition; delays in tumor growth were not observed using 
therapies that modestly diminished the number of Tregs in the tumor microenvironment. This study provides evidence that 
the recruitment of Tregs to the tumor microenvironment inhibits an effective antitumor immune response and highlights 
early Treg recruitment as a possible mechanism for the lack of response to immune checkpoint blockade antibodies in specific 
subtypes of cancer that are heavily infiltrated with adaptive immune cells.
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Results
Claudin-low tumors show increased expression of immune genes rela-
tive to other intrinsic subtypes of breast cancer. The original microar-
ray used to classify the intrinsic subtypes of breast cancer includ-
ed over 1,700 genes (21, 22), with an emphasis on cell-intrinsic 
transcriptional characteristics. We were interested in determining 
whether there were cell-extrinsic transcriptional differences that 
could be used to classify breast cancer subtypes. For this analysis, 
we evaluated the expression of 102 immune genes that encom-
pass downstream effector molecules, chemokines and chemok-
ine receptors, immune response signal mediators, cell-specific 
markers, and markers of oxidative stress, termed the intrinsic 
immune genes (IIGs) (Supplemental Table 1; supplemental mate-
rial available online with this article; https://doi.org/10.1172/
We show that patients with claudin-low tumors have an increased 
number of CD4+ T cells with focal increases in Tregs in the TME com-
pared with other intrinsic subtypes. To understand the mechanism 
for this, the p53–/– T11 and T12 genetically engineered mouse models 
(GEMMs) were used, which closely recapitulated the cell-intrinsic 
and -extrinsic characteristics of human claudin-low breast cancer. 
In human and mouse studies, gene expression profiling revealed 
increased expression of immune genes and Treg-associated genes 
in the claudin-low subtype. Importantly, checkpoint inhibition was 
found to be effective for claudin-low tumors only when combined 
with stringent Treg depletion. Taken together, these experiments 
highlight the role of Tregs in suppressing the immune response in 
claudin-low breast tumors and provide an understanding of the dif-
ferential response to immune checkpoint inhibition in breast cancer.
Figure 1. Human tumors exhibit differential immune gene 
expression. (A) Unsupervised hierarchical clustering of breast 
cancer samples from UNC337 by IIG list. (B) Overall expression of 
the immune gene signature by each subtype. (C) Representative 
H&E staining of human subtype–specific breast cancer. Original 
magnification, ×5. (D) Representative IF staining of human 
tumors for CD4 (red) and FoxP3 (green). Original magnification, 
×20. (E) Whole-slide scoring of CD4+ infiltrate for each subtype. 
(F) Unsupervised clustering by the IIGs in GEMMs (n = 59). Statis-
tical significance determined by Kruskal-Wallis test, with Dunn’s 
post-test for multiple comparisons. Data are presented as mean ± 
SEM. *P < 0.05; **P < 0.01.
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very high expression in T11 tumors (claudin-low). We generated a 
cell line from T11 tumors to standardize claudin-low tumor growth 
in vivo. Gene expression profiling of these tumors showed that the 
parental T11 tumor and tumors derived from injection of the T11 
cell line clustered tightly together within the claudin-low subtype, 
demonstrating that the T11 cell line is genetically quite similar to 
T11 tumor cells (Supplemental Figure 2).
Claudin-low tumors recruit increased numbers of immune cells to 
the tumor. Tumors representing the subtypes luminal A, HER2/Neu, 
and claudin-low were studied in GEMMs to evaluate the immune 
response during tumor progression. In order to evaluate both ear-
ly and late time points, tumors were harvested at approximately 20 
mm2 (Figure 2, A–D) or 100 mm2 (Figure 2, E–H), respectively, and 
analyzed by flow cytometry to determine the composition of TILs 
over time. FACS analysis work flows are shown in Supplemental 
Figure 3, and representative FACS plots are shown in Supplemen-
tal Figure 4. The total number of immune cells was significantly 
increased in T11 claudin-low tumors (Figure 2, A–H). Specifical-
ly, the number, but not the frequency, of CD4+FoxP3– T cells was 
increased in the TME in both 20-mm2 and 100-mm2 tumors (Figure 
2, A and E). Interestingly, we found an increase in the number of 
Tregs both at 20 mm2 and 100 mm2 in the T11 claudin-low model. 
There was a statistically significant increase in the number of CD19+ 
B cells in mice, with 20 mm2 T11 claudin-low compared with Neu 
tumors, and a significant increase in B cells in mice with 100 mm2 
T11 tumors compared with luminal A tumors (Figure 2, C and G). 
Additionally, we found very few CD8+ T cells in the TME of mice 
with either luminal A– or Neu-expressing tumors. There was a sta-
tistically significant increase in the number and frequency of CD8+ 
T cells in mice with 20-mm2 and 100-mm2 claudin-low tumors 
(Figure 2, B and F). There was an inverse correlation between the 
presence of Tregs and diminished number of both CD8+ T cells and 
CD19+ B cells (Figure 2, I and J). To confirm our results were not 
specific to the T11 cell line, we utilized an additional claudin-low 
tumor cell termed T12 to examine immune infiltration into the 
TME at late-stage tumor growth. We found an increase in Tregs in 
mice with 100 mm2 tumors in the T12 model, although the increase 
was not significant. We investigated the activation status of the cells 
migrating into the TME by looking at naive and memory T cell pop-
ulations (Supplemental Figure 5). Compared with luminal A– and 
Neu-expressing tumors, the T11 and T12 claudin-low tumors had 
increased effector memory cells in both the CD4+FoxP3– and CD8+ 
T cell populations. (Supplemental Figure 5, B and D). Thus, these 
data indicated that there was a significant difference in the popula-
tion of immune cells in the TME in mouse luminal A, Neu-express-
ing, or claudin-low tumors. Additionally, our data suggest that the 
early presence of Tregs was associated with diminished numbers of 
CD8+ T cells and B cells in mice with claudin-low tumors.
Tregs in mice with tumors show enhanced suppression and chemok-
ine production. Next, we evaluated whether the Tregs isolated from 
tumor-bearing mice were efficient at suppressing T cell responses. 
As shown (Figure 3, A and B), Tregs were capable of suppressing 
T cell proliferation in a mixed lymphocyte reaction assay. At high 
ratios of Treg/T effector cells (Teffs), Tregs were more effective 
when isolated from mice with 100-mm2 compared with 20-mm2 
tumors. Thus, tumor-bearing mice have functional Tregs that dis-
play enhanced suppression in mice with larger tumors.
JCI90499DS1). Gene expression profiling by microarray analysis 
was done on 337 breast tumors as previously described (23). Unsu-
pervised hierarchical clustering of UNC337 by only those genes in 
the IIG list divided patients into 3 clusters: low-expressing lumi-
nal, moderate-expressing HER2 enriched, and high-expressing 
basal-like and claudin-low tumors (Figure 1A). By gene expression 
signature quantification, HER2-expressing tumors had signifi-
cantly lower immune gene expression than claudin-low tumors 
(P < 0.05) (Figure 1B). Furthermore, claudin-low tumors showed 
significantly increased expression of a gene signature associated 
with Treg activity (P = 0.001, data not shown).
To confirm these findings, we performed transcriptome eval-
uation using the IIG classifier from a previous published breast 
cancer database (Molecular Taxonomy of Breast Cancer Inter-
national Consortium [METABRIC]; http://www.cbioportal.org/
study?id=brca_metabric#summary), as the stringency filter for 
tumor purity eliminated the inclusion of claudin-low tumors from 
the TCGA database (https://cancergenome.nih.gov/). Unsu-
pervised hierarchical clustering of the METABRIC data by only 
those genes in the IIG list revealed that clinical breast cancer sam-
ples divided into 3 clusters: low-expressing luminal, moderate- 
expressing HER2 enriched, and high-expressing basal-like and 
claudin-low tumors similar to what was shown in the UNC337 
data (Supplemental Figure 1). The claudin-low subtype had a sig-
nificantly increased immune gene expression compared with the 
other subtypes in the METABRIC data set (P < 0.0001).
Claudin-low breast tumors show increased infiltration by CD4+ 
cells. In order to determine whether IIG expression was associated 
with differences in Th cells, Tregs, or cytotoxic T cells (Tc cells), 
patient biopsy samples were studied by histology and immunoflu-
orescence (IF). Figure 1C shows H&E stains of the greatest area of 
immune infiltration of a representative luminal A and claudin-low 
tumor. Tumor tissue slides were analyzed for Tc cells (CD8+), 
Th cells (CD4+FoxP3-), and Tregs (CD4+FoxP3+). Representative 
images of CD4 and FoxP3 IF staining from the highlighted areas 
shown in Figure 1C demonstrate CD4+FoxP3+ cell infiltration 
into the tumor (Figure 1D). Claudin-low tumors recruited signifi-
cantly more CD4+ T cells to the tumor site than luminal A tumors 
(P = 0.002; Figure 1E), with areas of focally increased num-
bers of Tregs (Figure 1D). No differences in the number of CD8+ 
T cells were found across the different intrinsic subtypes (data 
not shown). These data indicate the heterogeneity of the immune 
response in breast cancer subtypes, with claudin-low tumors hav-
ing a significantly increased T cell infiltrate (P < 0.01) with focally 
increased numbers of Tregs. In contrast, luminal tumors showed 
an extremely limited number of CD8+ and/or CD4+ T cells.
Claudin-low GEMMs closely recapitulate human claudin-low 
breast cancer. Given the difficulties with standardizing tumor laten-
cy using clinical samples and the extreme difficulty evaluating the 
TME at the onset of tumor formation, we sought an in vivo meth-
od to better evaluate mechanisms for immune infiltration in clau-
din-low breast cancer. For this analysis, we used GEMMs of the 
claudin-low subtype, which have been found to be genotypically 
similar to human claudin-low tumors (24). Unsupervised cluster-
ing of the GEM models using the IIG list (Figure 1F) recreated the 
clustering profile seen in human samples with very modest expres-
sion of immune genes in 2250 tumors (luminal A) compared with 
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Figure 2. T11 and T12 (claudin-low) tumors recruit elevated numbers of immune cells to the tumor site. WT mice were injected with 1 × 106 2250 tumor 
cells or 1 × 104 T11 or T12 cells. Neu-N mice were injected with 5 × 104 NT2 cells. Tumors were harvested at 20 mm2 (2250, n = 9; NT2, n = 10; T11, n = 12) (A–D) 
or 100 mm2 (2250, n = 10; NT2, n = 5; T11, n = 10; T12, n = 6) (E–H), digested, enriched for lymphocytes, and analyzed by FACS. (A) CD4+ TILs, 20 mm2. (B) 
CD8+ TILs, 20 mm2. (C) CD19+ TILs, 20 mm2 (2250, n = 4). (D) CD4+FoxP3+ TILs, 20 mm2. (E) CD4+ TILs, 100 mm2. (F) CD8+ TILs, 100 mm2. (G) CD19+ TILs, 100 
mm2. (H) CD4+FoxP3+ TILs, 100 mm2. (I) Correlation between the percentage of CD8+ T cells and FoxP3+CD4+ T cells in mice with 20 mm2 T11 tumors. n = 16 
mice. (J) Correlation between CD19+ B cells and FoxP3+CD4+ T cells in T11 mice with 20 mm2 tumors. n = 16 (taken from the same group as evaluated in I). 
Statistical significance determined by Kruskal-Wallis test with Dunn’s post-test for multiple comparisons. Data are presented as mean ± SEM. *P < 0.05; 
**P < 0.01; ***P < 0.001; ****P < 0.0001.
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However, and unexpectedly, FACS analysis of the immune cells 
infiltrating the tumor showed that Tregs had the highest levels of 
PD-1 and CTLA-4 expression, as measured by FACS mean fluores-
cence intensity (MFI) (Figure 6, A–D).
Depletion of Tregs delays T11 tumor growth. The inverse correla-
tion between the presence of Tregs and the absence of CD8+ T cells 
and CD19+ B cells in the TME (Figure 2, I and J) led us to hypoth-
esize that approaches that target Tregs would enhance the antitu-
mor immune response. To deplete Tregs, we made use of mice in 
which the diphtheria toxin (DT) receptor had been knocked in to 
the FoxP3 locus (DEREG mice) and treated with DT to specifically 
deplete Tregs in vivo. DEREG mice given DT exhibited a signifi-
cant delay in tumor growth and a nonsignificant improvement in 
survival (Figure 7, A and B), with all mice eventually succumbing 
to either autoimmunity or tumor. As an alternative nongenetic 
approach to treatment, tumor-bearing WT mice received a single 
treatment of low-dose (100 mg/kg) cyclophosphamide (Cy) to 
selectively deplete Tregs (25). As with DT treatment of DEREG 
mice, a single injection of low-dose Cy significantly delayed 
tumor growth (Figure 7, A and B), but again, all mice eventually 
succumbed to death upon tumor administration. While Treg num-
bers were decreased compared with those in untreated T11 tumors 
after Cy, they had increased to above baseline by the time tumors 
reached 20 mm2 (Figure 7C). Thus, Treg depletion alone appeared 
to modestly affect tumor growth.
Depletion of Tregs plus checkpoint inhibition improved survival 
and increased cytokine production by CD8+ T cells. While depleting 
Tregs delayed tumor growth, we evaluated whether addition of 
checkpoint inhibition therapy would enhance the benefit. Giv-
en the finding that blocking CXCR4 had a modest effect on the 
recruitment of Tregs in T11 tumors, we initially evaluated wheth-
er combining checkpoint inhibition with AMD3100 would have 
an impact on tumor growth. There were no synergistic effects 
between CXCR4 inhibition and checkpoint inhibition, as we found 
no difference in tumor growth using combined checkpoint inhibi-
tion and control treatment or AMD3100 (Supplemental Figure 7, A 
and B). Mice receiving AMD3100 had a reduction in Tregs 12 days 
after the onset of treatment (Supplemental Figure 7, C and D), but 
by day 16, the reduction in infiltrating immune cells was no longer 
specific to Tregs, as we saw a reduction in CD4+ and CD8+ T cells 
(Supplemental Figure 7, E and F). When combined with check-
point inhibition, all cell subsets were significantly reduced in the 
To determine what mediators were responsible for recruiting 
Tregs to the claudin-low tumor site, we compared gene expres-
sion differences between Neu-expressing and claudin-low tumors 
(Figure 4A). T11 tumors expressed significantly higher levels of 
multiple chemokines, with CXCL12 being 22-fold higher in these 
tumors compared with Neu-expressing tumors (95% CI: 17.1 – 28.3; 
P < 0.001). ELISA of tumor homogenate for CXCL12 confirmed the 
array findings, with claudin-low tumors expressing higher levels 
of CXCL12 protein than Neu-overexpressing tumors (Figure 4B). 
Elevated levels of CXCL12 protein were also found in the serum of 
claudin-low tumor-bearing mice (Figure 4C). Tregs that infiltrate 
T11 tumors demonstrated higher expression levels of CXCR4, a 
receptor for CXCL12, compared with conventional CD4+ T cells 
(P = 0.03) or CD8+ T cells (P = 0.003; Figure 4, D and E).
To evaluate whether the CXCL12/CXCR4 axis was critical to 
the recruitment of Tregs in mice with claudin-low tumors, mice 
were treated with the CXCR4 inhibitor AMD3100. There was 
a trend toward decreased Treg numbers in AMD3100-treated 
mice (Figure 5A), which was greater when comparing the number 
of FoxP3+PD-1+ Tregs, where PD-1 indicates programmed death 
receptor 1 (P = 0.07) (Figure 5B). To further evaluate whether the 
CXCL12/CXCR4 axis was critical to the recruitment of Tregs, 
shRNA knockdown of CXCL12 was achieved by lentiviral expres-
sion of CXCL12-targeted shRNA into T11 tumor cells. (Figure 5, 
C and D). We generated 2 cell lines, one with a 55% knockdown 
of CXCL12 (KD1) and one with an 85% knockdown (KD5). There 
was a nonsignificant reduction in both Tregs and PD-1+ Tregs in 
the TME using the more robust knockdown of CXCL12 at day 13 
post tumor implantation (PTI) (Figure 5, E and F). Thus, these 
data indicate that inhibition of the CXCL12/CXCR4 axis in vivo 
had a modest but not significant effect on Treg accumulation in 
claudin-low tumors.
Checkpoint inhibition therapy does not alter T11 tumor growth. 
Because of the increased number of immune cells infiltrating the 
tumor, we hypothesized that the T11 claudin-low model would 
be responsive to checkpoint inhibition therapy with blocking 
antibodies against the inhibitory receptors PD-1 and cytotoxic T 
lymphocyte–associated protein 4 (CTLA-4). Surprisingly, check-
point inhibition therapy conferred no benefit on tumor growth or 
survival in the T11 claudin-low model (Figure 6, E and F), despite 
expression of PD-1 on CD8+ T cells (Figure 6A). This result was 
confirmed in the T12 claudin-low model (Supplemental Figure 6). 
Figure 3. FoxP3+ cells from T11 tumor–
bearing mice are functionally suppres-
sive. FoxP3GFP mice were injected with 5 
× 104 T11 cells. GFP+FoxP3+ splenocytes 
were sorted from tumor-bearing mice at 
(A) 20 mm2 or (B) 100 mm2 and plated 
with irradiated allogeneic stimulator cells 
and different ratios of WT Teffs for 3 
days. Teffs were then FACS analyzed for 
dilution of proliferation dye. n = 3 mice at 
each tumor size. Data are presented as 
mean ± SEM.
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TME (Supplemental Figure 7, C–E). As a more rigorous test, Tregs 
were depleted using DT treatment in DEREG mice in combination 
with anti–CTLA-4 and anti–PD-1 monoclonal antibody treatment. 
Tregs were depleted from approximately 20% to 5% after DT treat-
ment (Figure 8F). T11 tumor–bearing mice were followed for 25 
days PTI until tumor growth reached 170 mm2 or mice developed 
significant autoimmunity from Treg depletion. Treg depletion in 
combination with anti–PD-1 and anti–CTLA-4 therapy resulted 
in decreased tumor growth and significantly improved survival 
(P = 0.03) (Figure 8, A and B). Unfortunately, because mice treat-
ed with DT developed severe autoimmunity, we were unable to 
extend the tumor growth curves past 25 days PTI per institutional 
IACUC guidelines. We then sought to determine whether delayed 
tumor growth was correlated with increased cytokine production 
by T cells. We analyzed IFN-γ production by CD8+ T cells in both 
the tumor and the spleen by FACS as a measure of productive 
CD8+ T cell responses. While this evaluation was limited greatly 
by the significant occurrence of autoimmunity in mice treated 
with DT, there was a nonsignificant increase in the percentage of 
CD8+ T cells that generated IFN-γ, but not in total CD8+ T cells, 
in mice treated with DT that also received checkpoint inhibition 
therapy (Figure 8, C–E).
To circumvent the issues with autoimmunity in mice given DT 
treatment prior to tumor implantation, we treated a small group 
of mice with DT PTI. While we were limited again in the ability to 
generate significant numbers of DEREG mice to evaluate, there 
was prolonged survival until day 40 for half of the mice given DT 
therapy PTI (Supplemental Figure 8). Because of the autoimmu-
nity associated with the use of DEREG mice, we sought a phar-
macological approach to suppress Treg function in vivo. Previous 
work has shown that selective inhibition of the p110δ isoform of 
PIK3 using a small molecule inhibitor delayed 4T1 tumor growth 
in mice and reduced Treg suppression (26). We used the small 
molecule inhibitor PI-3065 in addition to checkpoint inhibition in 
our T11 claudin-low model. Treatment with PI-3065 was associat-
ed with a statistically significant improvement in survival, with a 
period of tumor stability in half of the treated mice (Supplemental 
Figure 9, A and B). However, we were not able to mediate tumor 
Figure 4. T11 tumors express high levels of CXCL12. (A) Whole-tumor RNA was 
isolated and analyzed using the PAMM-011 RT2 Profiler PCR Array. Gene expression is 
presented relative to NT2 tumor controls. (B) Tumors were harvested on day 21 PTI, 
homogenized, and analyzed by CXCL12 ELISA (n = 3–4 per group). (C) Serum was har-
vested on day 21 PTI and analyzed for CXCL12 ELISA (n = 3 per group). (D) Representa-
tive overlay of CXCR4 expression by CD4+FoxP3+ Tregs (Treg CD4), CD4+FoxP3– T cells 
(Non-Treg CD4), and CD8+ T cells. (E) MFI values for the expression of CXCR4 from TILs 
isolated from mice with 20 mm2 T11 tumors (n = 6). Statistical significance was deter-
mined by Student’s t test (B and C) or Mann-Whitney U test (E). Data are presented as 
mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
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regression or affect overall survival. Treatment with PI-3065 and 
checkpoint therapy did significantly reduce the number of Tregs 
infiltrating into the tumor (Supplemental Figure 8C). However, 
it also led to a reduction in the number of CD4+ FoxP3-negative 
T cells accumulating in the TME.
Discussion
Triple-negative breast cancer has the worst prognosis of the his-
tologic subtypes due to presenting at higher grade at diagnosis, 
increased recurrence risk following treatment, and shortened 
time to metastasis (27). The paradoxical observation that the 
molecular subtypes comprising these tumors also exhibit high lev-
els of immune cell infiltration suggests that these infiltrating cells 
may have a deleterious impact on patient outcome. Our study sup-
ports this conclusion for claudin-low breast cancer. Clustering by 
the IIG alone was sufficient to separate triple-negative basal-like 
and claudin-low tumors from luminal tumors and HER2- enriched 
tumors. This finding was not due to aberrant gene expression 
by tumor cells, but to increased immune cell infiltration into 
the tumor, especially CD4+ T cells. These results are in contrast 
with those in prior studies where numbers of TILs were found to 
be favorably prognostic in breast cancer (5). Importantly, these 
studies did not stratify breast tumors by molecular subtype, high-
lighting that the significance of the immune infiltrate may vary 
Figure 5. Role of CXCL12/CXCR4 path-
way in Treg infiltration into claudin-low 
tumors. (A and B) WT mice were implanted 
on day –2 with osmotic pumps loaded with 
PBS or 10 mg AMD3100 in PBS (n = 7 per 
group) and challenged with 1 × 104 T11 cells. 
Tumors were harvested on day 12 PTI and 
FACS analyzed. (A) Percentage and number 
of CD4+FoxP3+ TILs. (B) Percentage and 
number of CD4+FoxP3+PD-1+ TILs. (C) T11 
cell line was transfected with lentiviral-ex-
pressing CXCL12-targeted shRNA, and (D) 
CXCL12 knockdown was confirmed using 
CXCL12 ELISA. (E and F) WT mice were 
injected with 1 × 104 cells of WT, scramble, 
or knockdown (KD) lines (n = 5 per group). 
Tumors were harvested on day 13 PTI 
and FACS analyzed. (E) Percentage and 
number of CD4+FoxP3+ TILs. (F) Percent-
age and number of CD4+FoxP3+PD-1+ TILs. 
Statistical significance was determined by 
Mann-Whitney U test. Data are presented 
as mean ± SEM.
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Tregs dominated the immune response, which 
was associated with diminished numbers of 
CD19+ B cells and CD8+ T cells. Thus, there 
may be a critical early period when tumors can 
recruit sufficient numbers of Tregs to abrogate 
a functional adaptive immune response.
We sought to determine the mechanism 
that accounts for the preferential recruitment 
of Tregs to claudin-low tumors. CXCL12, a 
chemokine critical for the homing of hemato-
poietic stem cells (32), was expressed in mice 
22-fold more with claudin-low compared with 
Neu tumors. Further, Tregs that infiltrated 
claudin-low tumors expressed high levels of 
CXCR4, one of the receptors for CXCL12. Inhi-
bition of CXCR4 with AMD3100 demonstrat-
ed a modest role for this axis in Treg recruit-
ment. AMD3100-treated mice demonstrated a 
trend for decreased Treg numbers in the tumor 
compared with controls, which contained elevated PD-1+ Tregs. 
However, the modest decrease in the recruitment of Tregs found 
using AMD3100 was not sufficient to augment the antitumor 
immune response using checkpoint inhibitor therapy, in part 
because exposure to AMD3100 also diminished the recruitment 
of CD4+ non-Tregs and CD8+ T cells to the TME. Similarly, selec-
tive inhibition of p110δ isoform of PI3K using a small molecule 
inhibitor plus checkpoint inhibition reduced the number of Tregs, 
which was associated with a significant (P < 0.05) improvement 
in tumor growth compared with that in control mice receiving 
checkpoint inhibition alone. Unfortunately, this combination did 
not result in tumor regression or enhanced overall survival. Our 
data suggest that robust and specific Treg depletion is necessary to 
engender an effective antitumor response. This level of depletion 
in our mouse studies was associated with profound autoimmunity. 
Thus, it is not clear whether prolonged, robust Treg depletion in 
patients could be tolerated to enhance checkpoint inhibitor thera-
py for the treatment of claudin-low tumors.
The function of PD-1 on the surface of Tregs is not entirely 
known (33, 34). PD-1hi Tregs in the TME in glioma patients have 
been found to be exhausted, yet capable of generating proinflam-
matory cytokines, such as IFN-γ (35). This suggests that one mech-
anism for the impaired function of anti–PD-1 antibody therapy is 
the presence of PD-1–expressing Tregs that can (a) bind antibody 
widely by subtype. The use of mouse models that mimic human 
tumor biology is critical for finding pathways important for tumor 
pathogenesis and potential. The GEMMs utilized by our laborato-
ry are derived from and studied in immunocompetent mice that 
recapitulate tumor biology at the genetic and whole tumor level. 
As expected by similarity to the human patient samples, murine 
tumors exhibited substantial differences in immune cell infiltra-
tion based on intrinsic subtype.
Recently, there has been intense interest in biomarkers of 
response to checkpoint inhibitor therapy. One stratification 
that has been proposed for patients with melanoma is immune- 
excluded versus immune-infiltrated tumors, with data suggesting 
that checkpoint inhibition is not effective in immune-excluded 
tumors (28). Our data would suggest that a third group of tumors, 
those that are actively immune suppressed, may also not respond 
to checkpoint inhibition. The presence of Tregs as a biomarker for 
antitumor response has been confusing, with data indicating both 
negative and positive clinical benefits (29–31). This may be due 
to the critical issue of timing in the evaluation of Tregs from the 
TME. In claudin-low murine tumors, Tregs made up as much as 
60% of all CD4+ cells in the tumor and were present in substantial 
numbers prior to the expansion of other adaptive immune cells. 
These cells were both functional and durable, with continued 
presence as the tumors grew. In many of the T11 and T12 tumors, 
Figure 6. Tumor-infiltrating Tregs express increased 
levels of PD-1 and CTLA-4; however, PD-1 and 
CTLA-4 inhibition does not increase survival in 
T11 tumor–bearing mice. (A) Representative FACS 
overlay and (B) total MFI values of PD-1 expression 
by T11 TILs at 20 mm2. n = 4. (C) Representative FACS 
overlay and (D) total MFI values of CTLA-4 expres-
sion by T11 TILs at 20 mm2. n = 5. (E) Growth curves 
of T11 tumor–bearing mice receiving anti–PD-1 and 
anti–CTLA-4. (F) Survival analysis of data presented 
in E (n = 5 for each group). Statistical significance 
was determined by Mann-Whitney U test. Data are 
presented as mean ± SEM. *P < 0.05.
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microarrays (Agilent Technologies) (18, 19). We used the microarray 
data set previously published as the UNC337 data set in the NCBI’s 
Gene Expression Omnibus (GEO GSE18229) (4). All microarray and 
patient clinical data are available in the University of North Carolina 
Microarray Database (ref. 20; https://genome.unc.edu/cgi-bin/SMD/
publication/viewPublication.pl?pub_no=81). The probes for all analy-
ses were filtered by requiring the lowest normalized intensity values 
in both sample and control to be greater than 10. The normalized 
log2 ratios cyanine-5 (Cy5) dye intensity for experimental sample/ 
cyanine-3 (Cy3) dye intensity for reference of probes mapping to the 
same gene (EntrezGene ID as defined by the manufacturer) were 
averaged to generate independent expression estimates. The META-
BRIC data set contains 1,981 samples derived from breast tumors of 
patients participating in the METABRIC trial (39). Gene expression 
data were acquired by Illumina HT-12.
Mouse breast tumor microarray data sets. All mouse samples from 
fresh-frozen invasive breast carcinomas were analyzed as described 
previously, using Agilent mouse oligo microarrays (18). Data normal-
ization and preprocessing were identical to those described for the 
UNC337 data set. We used 2 samples obtained from the combined 
data set previously published (GEO GSE3165, GSE8516, GSE9343, 
GSE14457, GSE15263, GSE17916, GSE27101, and GSE42640) (21). 
The remaining 57 samples represent newly obtained tumor sam-
ples using methods approved by IACUC guidelines. Total RNA was 
purified from 20 to 30 mg of mouse mammary tumor using the QIA-
GEN RNeasy Mini Kit following the manufacturer’s protocols. RNA 
quantity and quality were determined using the Nanodrop spectro-
photometer and Agilent Bioanalyzer, respectively. Total RNA was 
reverse transcribed and labeled with Cy5 dye for experimental sam-
ples and Cy3 dye for mouse reference samples using the Agilent Low 
RNA Input Fluorescent Linear Amplification Kit (18). Equal quanti-
ties of labeled mouse reference RNA and tumor RNA were cohybrid-
ized overnight to Agilent microarrays, washed, and scanned; signal 
intensities were then determined.
Microarray data analysis. Hierarchical clustering of the UNC337 
data set to group samples by intrinsic subtype was performed using 
the intrinsic gene list as described. (22). Centroid linkage hierarchical 
clustering was performed using Cluster v3.0 (23). Student’s t tests for 
gene expression data were performed using R (24).
if PD-1 is preferentially expressed on these cells and (b) become 
activated in the presence of anti–PD-1 antibody. Our data requir-
ing depletion of Tregs to mediate the antitumor activity of anti–
PD-1 antibody therapy would be consistent with this mechanism.
In summary, we have found that claudin-low tumors are high-
ly enriched with Tregs. Enhancing the immune response to these 
tumors by depleting Tregs in addition to immune checkpoint inhi-
bition impaired tumor growth and prolonged survival, but was 
insufficient to mediate tumor regression. Generation of CXCL12 
by the tumor cells played a modest role in the recruitment of Tregs 
to the tumor site. These studies suggest that future clinical trials 
for patients with triple-negative breast cancer should target the 
immunosuppressive environment generated by the tumor in com-
bination with checkpoint inhibition.
Methods
Mice and cell lines. BALB/cJ and C57BL/6J (B6) females and C.B6-Tg(-
Foxp3-DTR/EGFP)23.2Spar/Mmjax (DEREG) females were purchased 
from The Jackson Laboratory. Neu-N mice were purchased from 
Charles River Laboratory. Female mice (8 to 14 weeks) were used for all 
experiments. Rat Neu-expressing NT2 cells (HER2/Neu) and the 2250 
(luminal A), 2225 (basal-like), and T11 (claudin-low) tumor models 
have been described (36–38). T12 cells were prepared by harvesting a 
T12 tumor from a tumor-bearing mouse, followed by manual digestion 
with razor blades and chemical digestion with Liberase TM (Roche) 
and DNase I (Sigma-Aldrich). Digestion was stopped by the addition of 
EDTA. The 2250 cells were prepared by harvesting a 2250 tumor from a 
tumor-bearing mouse, followed by manual digestion with razor blades 
and chemical digestion as described above. BALB/c mice were injected 
with 1 × 106 2250 cells (luminal A) in Matrigel HC low-growth factor, 1 × 
104 or 1 × 105 T12 (claudin-low) cells in Matrigel HC low-growth factor, 
or 1 × 104 T11 (claudin-low) cells in PBS. Neu-N mice were injected with 
5 × 104 NT2 cells (Neu) in PBS. Tumors were orthotopically transplant-
ed by intradermal injection into a mammary fat pad and measured as 
previously described (11). Blood and serum samples were harvested by 
cardiac puncture at the termination of the experiment.
Human breast tumor microarray data sets. All human tumor and 
normal tissue samples were obtained from fresh-frozen invasive breast 
carcinomas that were profiled, as described previously, using oligo 
Figure 7. Treg depletion delays tumor growth in the absence of adoptive transfer. WT untreated, Cy-treated, and DEREG mice were injected with 1 × 104 
T11 cells (n = 5 per group). Cy-treated mice received 100 mg/kg Cy on day +2. DEREG mice received 1 μg DT on days –1, 0, +6, and +7. (A) Growth curves. (B) 
Survival. There was a significant difference in survival between both Treg-depleted groups compared with the untreated control group (P < 0.05; log-rank 
test), but not between treated groups. (C) Treg numbers following a single dose of Cy were reduced compared with those in untreated T11 tumors. Statisti-
cal significance was determined by Mann-Whitney U test. Data are presented as mean ± SEM. ***P < 0.001; ****P < 0.0001.
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the Bond Polymer Refine Detection Kit (DS9800, Leica Microsys-
tems). Slides were deparaffinized in Bond Dewax Solution (AR9222) 
and hydrated in Bond Wash Solution (AR9590). Antigen retrieval 
was done at 100°C either in Bond Epitope Retrieval Solution 1, pH 
6.0 (AR9661), or in Solution 2, pH 9.0 (AR9640). IHC slides were 
H&E and IF analyses of patient samples. Staining was performed 
on tumor-infiltrating lymphocytes in 85 breast cancer whole tissue 
sections (WTS) obtained from UNC hospitals surgical pathology 
archive. IHC and dual IF on WTS with immune infiltrates were per-
formed with the Bond fully automated slide-staining system using 
Figure 8. Treg depletion with anti–PD-1 and anti–CTLA-4 
immune checkpoint inhibition significantly delays T11 
tumor growth. WT or FoxP3-DTR mice were injected with 
1 × 104 T11 cells. DEREG mice received 1 μg DT on days –1, 
0, 6, and 7 PTI. DT + PD-1 + CTLA-4 mice received 1 μg 
DT on days –1, 0, 6, and 7 PTI and anti–PD-1 and anti–
CTLA-4 antibody on day –1, then every other day for the 
duration of the experiment. Tumor growth evaluation was 
terminated at day 25 PTI due to autoimmune manifes-
tations and tumor growth reaching an end point of 170 
mm2. (A) Mice depleted of Tregs and receiving anti–PD-1 
and anti–CTLA-4 (n = 3) had a significant survival benefit 
compared with untreated mice (n = 4) or those treated 
with anti–PD-1 and anti–CTLA-4 alone (n = 3) (CLTLA4 + 
PD-1 vs. DT + CLTLA4 + PD-1: P = 0.03; log-rank test). (B) 
Individual replicates of tumor growth curves. (C–E) Mice 
treated with anti–PD-1 and anti–CTLA-4 alone (Treg+) (n 
= 3) or anti–PD-1 and anti–CTLA-4 with DT (Treg–) (n = 3). 
Mice were sacrificed 25 days PTI and FACS analyzed for 
percentage of CD8+ T cells and IFN-γ production by CD8+ 
T cells in tumor and spleen. (C) Representative FACS plot 
of IFN-γ production by CD8+ T cells from tumor or spleen 
of tumor-bearing mice. (D) Percentage of CD8+ T cells and 
IFN-γ production by CD8+ T cells from tumor. (E) Percent-
age CD8+ T cells and IFN-γ production by CD8+ T cells in 
spleen. (F) Percentage and total number of CD4+FoxP3+ 
Tregs from tumors in mice treated with anti–PD-1 and 
anti–CTLA-4 alone (Treg+) (n = 3) or anti–PD-1 and anti–
CTLA-4 with DT (Treg–) (n = 3). Analysis of T cell TILs was 
not possible after day 25 in DT-treated mice due to severe 
autoimmunity necessitating termination of the experi-
ment at that time. Data are presented as mean ± SEM.
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immune checkpoint inhibition received i.p. injection of 100 μg anti–
CTLA-4 (9D9), 200 μg anti–PD-1 (J43), or isotype antibody on day –1 
PTI and then every other day throughout the experiment (40, 41).
Mice undergoing Treg depletion (DEREG mice) received i.p. injec-
tions of 1 μg DT in PBS on days –1, +1, +6, and +7 (27). Mice undergoing 
specific inhibition of p110δ PI3K were given drug (75 mg/kg PI-3065, 
once daily) or vehicle (0.5% methylcellulose with 0.2% Tween 80) by 
oral gavage from day +1 through the duration of the experiment (26).
Treg-suppression assay. For the Treg-suppression assays, we eval-
uated splenic Tregs. FoxP3+GFP+ cells were sorted using a MoFlo 
Cell Sorter (Beckman Coulter). Stimulator cells were isolated from 
WT B6 splenocytes following CD90 microbead depletion (Miltenyi 
Biotec) and irradiation at 2,100 centigray (cGy). Responder cells 
were isolated from WT BALB/c mice using the Cedarlane T Recovery 
Column Kit. Isolated cells were then B220 and CD25 depleted using 
phycoerythrin-conjugated (PE-conjugated) antibodies and anti-
PE magnetic bead sorting (Miltenyi Biotec). Responder cells were 
stained with the Cell Proliferation Dye eFluor 670 (eBioscience) and 
plated at varying Treg/Teff ratios. Cells were cocultured for 3 days, 
stained, and FACS analyzed.
Real-time PCR array. Whole tumor RNA was isolated using the 
RNEasy Kit (QIAGEN) and reverse transcribed. Real-time PCR was 
performed on the ABI 7300 (Applied Biosystems Inc.), using Mas-
ter Mix from the Mouse Inflammatory Cytokines and Receptors 
(PAMM-011) RT2 Profiler PCR Array System (QIAGEN). Ct values 
were determined by ABI software. Data analysis was performed 
using the web-based RT2 Profiler PCR Array Data Analysis version 
3.5 (QIAGEN).
AMD3100 and Cy. Alzet osmotic pumps, model 2002 (Alza), were 
loaded with 10 mg AMD3100 (Tocris) dissolved in PBS. Control mice 
received pumps loaded with PBS without AMD3100 (28). Pumps were 
subcutaneously implanted dorsally on day –2. Mice were then chal-
lenged with 1 × 104 T11 cells, and tumors were harvested 12 days later 
at approximately 20 mm2 in accordance with IACUC guidelines. For 
low-dose Cy studies, a single dose of 100 mg/kg Cy was given PTI. 
This dose was sufficient to deplete 60% of the Tregs for approximately 
8 days with rebound increases above baseline at day 12 after therapy 
(data not shown).
CXCL12 knockdown. T11 cells were treated with 4 μg/ml Polybrene 
and cultured overnight with Mission shRNA Lentiviral Transduction 
Particles (Sigma-Aldrich) containing shRNA specific for CXCL12 or a 
nontarget control (scramble) at an MOI of 10. Lentiviral particles were 
removed the next morning and new medium was added. The following 
day, cells were cultured in medium containing 6 μg /ml puromycin and 
expanded to select for transduced cells. Cells were tested for CXCL12 
production by real-time PCR and ELISA. Two different knockdown 
cell lines with different levels of knockdown of CXCL12, as evaluated 
by ELISA assay, were characterized. Knockdown of CXCL12 had no 
impact on the growth of T11 cells in vitro (data not shown).
Statistics. Data are presented as mean ± SEM. Statistical differ-
ences were determined using Student’s t test, Mann-Whitney U test, 
or Kruskal-Wallis test, with Dunn’s post-test for multiple comparisons 
where appropriate. Survival data are presented using Kaplan-Meier 
survival analysis. Survival results were analyzed using the log-rank 
test. Statistical analyses were conducted using GraphPad Prism 6 soft-
ware, unless otherwise noted. Results were considered statistically 
significant at P ≤ 0.05.
visualized with DAB and counterstained with hematoxylin using 
Bond Polymer Refine Detection. Stained slides were dehydrated. 
IF slides were counterstained with Hoechst 33258 (Invitrogen) and 
mounted with ProLong Gold antifade reagent (P36934, Life Tech-
nologies). Tumor tissue slides (n = 10 per subtype) were stained for 
CD8, CD4, and FoxP3 and analyzed for coexpression at the cellu-
lar level using TissueStudio on-slide cytometry to measure tumor 
infiltration by Tc cells (CD8+), Th cells (CD4+FoxP3-), and Tregs 
(CD4+FoxP3+). All samples were evaluated by pathologists blinded 
to the tumor subtype.
Imaging and digital image analysis. H&E and IF–stained slides 
(CD4, CD8, CD19, and FoxP3) were digitally imaged at 20× magnifi-
cation using the Aperio ScanScopes XT and FL (Aperio Technologies). 
The hematoxylin and DAB OD parameters were adjusted for both 
algorithms. The nuclear segmentation factor and the weak positive 
threshold were tuned for the cytoplasmic v2 and the color deconvo-
lution v9 algorithms, respectively. High-resolution acquisition (20× 
objective) of the stained slides in the DAPI, Cy3, and Cy5 channels 
was performed in the Aperio ScanScope FL (Aperio Technologies). 
Cell nuclei were visualized in the DAPI channel; CD8, CD19, and 
FoxP3 were visualized in the Cy3 channel; CD4 was visualized in the 
Cy5 channel. To determine the number of cells coexpressing FoxP3/
CD4, slides were analyzed using Definiens Tissue Studio image analy-
sis software (Architect XD v 2.0.4, Tissue Studio v 3.5).
Antibodies and flow cytometry reagents: human antibodies. Mouse 
monoclonal antibodies against human CD4 (clone 4B12), CD8 (clone 
4B11), and CD19 (clone BT51E) were purchased from Leica Microsys-
tems. FoxP3 (clone 236A/E7) was purchased from Abcam. CD279 
(PD-1, clone J105) was purchased from eBioscience.
Antibodies and flow cytometry reagents: mouse antibodies. Flow 
cytometry monoclonal antibodies against murine CD4 (GK1.5 or 
RM4-5), CD8 (53-6.7), PD-1 (J43 or RMP1-30), CD45 (30-F11), 
CD62L (MEL-14), and CXCR4 (2B11) were purchased from eBiosci-
ence. CD19 (6D5) and CD44 (IM7) were purchased from BioLegend. 
Intracellular antibodies FoxP3 (FJK-16s), TNF (MP6-XT22), IFN-γ 
(XMG1.2), and Helios (22F6) were purchased from eBioscience. Cell 
viability was determined using Blue or Aqua Fluorescence Reactive 
Dye (Life Technologies).
Flow cytometry. Cells were surface stained, fixed, and permeabi-
lized overnight using the Foxp3/Transcription Factor Staining Buffer 
Set (eBioscience), and intracellular staining was performed the fol-
lowing day according to the manufacturer’s instructions. Data were 
acquired using MACSQuant (Miltenyi Biotec), BD Canto, or LSR II (BD 
Biosciences). Acquired data were analyzed using FlowJo Flow Cytome-
try Analysis Software (Tree Star Inc.).
Isolation of murine TILs. Murine tumors were resected and 
digested in Liberase TM (Roche), DNase I (Sigma-Aldrich), hyalu-
ronidase (Sigma-Aldrich), and collagenase XI (Sigma-Aldrich), as 
previously described (25). Single-cell suspensions were enriched for 
lymphocytes by isolating cells at the interface of 44% Percoll (Sigma- 
Aldrich) in media and Lympholyte-M (Cedarlane) gradient. Isolated 
cells were stimulated for 4 hours in PMA/ionomycin prior to intra-
cellular cytokine staining.
In vivo cell inhibition and depletion. Monoclonal antibodies used for 
in vivo antibody inhibition and depletion were purchased from BioXCell 
or obtained from the laboratory of Bruce Blazar (University of Minneso-
ta, Minneapolis, Minnesota, USA) (anti–PD-1 mAb). Mice undergoing 
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